These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3481140)

  • 21. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation between plasma concentration of heparin and biological response determined by 2 APTT reagents of different sensitivities].
    Bassini E; Miceli M; Cini S; Francalanci R
    Quad Sclavo Diagn; 1986 Jun; 22(2):193-200. PubMed ID: 3823368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the activated partial thromboplastin time for heparin monitoring.
    Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
    Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of APTT monitoring of low-dose heparin dosage in hip surgery.
    Poller L; Taberner DA; Sandilands DG; Galasko CS
    Thromb Haemost; 1982 Feb; 47(1):50-3. PubMed ID: 7071805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The APTT response of pregnant plasma to unfractionated heparin.
    Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
    Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
    Elliott CG; Hiltunen SJ; Suchyta M; Hull RD; Raskob GE; Pineo GF; Jensen RL; Yeates S; Kitterman N
    Arch Intern Med; 1994 May; 154(9):999-1004. PubMed ID: 8179457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Is the activated partial thromboplastin time suitable for monitoring of thrombosis therapy with high-dose standard heparin?].
    Hürzeler C; von Felten A
    Schweiz Med Wochenschr; 1994 Apr; 124(17):712-9. PubMed ID: 8202668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Monitoring of heparin therapy].
    Camici M; Evangelisti L
    Minerva Med; 1993 Oct; 84(10):507-9. PubMed ID: 8247304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of aPTT in monitoring unfractionated heparin in children.
    Chan AK; Black L; Ing C; Brandão LR; Williams S
    Thromb Res; 2008; 122(1):135-6. PubMed ID: 17976694
    [No Abstract]   [Full Text] [Related]  

  • 31. Monitoring unfractionated heparin with the aPTT: time for a fresh look.
    Eikelboom JW; Hirsh J
    Thromb Haemost; 2006 Nov; 96(5):547-52. PubMed ID: 17080209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood.
    Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1988 Dec; 60(3):377-81. PubMed ID: 2853458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays.
    Nurmohamed MT; Berckmans RJ; Morriën-Salomons WM; Berends F; Hommes DW; Rijnierse JJ; Sturk A
    Thromb Haemost; 1994 Nov; 72(5):685-92. PubMed ID: 7900075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time.
    Dati F; Barthels M; Conard J; Flückiger J; Girolami A; Hänseler E; Huber J; Keller F; Kolde HJ; Müller-Berghaus G
    Thromb Haemost; 1987 Oct; 58(3):856-65. PubMed ID: 3433249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay.
    Kostousov V; Nguyen K; Hundalani SG; Teruya J
    Arch Pathol Lab Med; 2014 Nov; 138(11):1503-6. PubMed ID: 25357112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of the Heptest and a chromogenic substrate method to assess anticoagulation in patients refractory to heparinization by the activated partial thromboplastin time method.
    Messmore HL; Koza M; Farid S; Wehrmacher WH
    Semin Thromb Hemost; 1994; 20(4):351-2. PubMed ID: 7899867
    [No Abstract]   [Full Text] [Related]  

  • 37. Coacute heparin: a new simple monotest for monitoring heparin treatment.
    Friberger P; Urig E; Eriksson-Skoog L; Svensson S; Isacson C
    Semin Thromb Hemost; 1994; 20(4):328-32. PubMed ID: 7899863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin.
    Bates SM; Weitz JI; Johnston M; Hirsh J; Ginsberg JS
    Arch Intern Med; 2001 Feb; 161(3):385-91. PubMed ID: 11176764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring.
    Manzato F; Mengoni A; Grilenzoni A; Lippi G
    Clin Chem Lab Med; 1998 Dec; 36(12):975-80. PubMed ID: 9915232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of calcium ions on the activated partial thromboplastin time of heparinized plasma.
    Greenberg CS; Adams JP; Mullen PE; Koepke JA
    Am J Clin Pathol; 1986 Oct; 86(4):484-9. PubMed ID: 3766461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.